Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rigosertib versus physician's choice after hypomethylating agent failure in higher-risk myelodysplastic syndrome
NL-OMON47424Phase 3Withdrawn
- Sponsor
- Onconova Therapeutics, Inc.
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rigosertib in myelodysplastic syndrome (MDS) (2 arms), sponsored by Onconova Therapeutics, Inc. Primary endpoints: Overall survival in all randomized patients and Overall survival in IPSS-R very high risk subgroup. Planned start Nov 2016; status: withdrawn.
02
Drugs
rigosertib
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON47424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47424.